Drug Profile

HC 017 AA

Alternative Names: HC017AA

Latest Information Update: 05 Sep 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator HCell
Class Anti-inflammatories; Skin disorder therapies
Mechanism of Action Angiogenesis inducing agents

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Alopecia areata
New Molecular Entity Yes

Highest Development Phases

Preclinical Alopecia areata

Most Recent Events

05 Sep 2024 HC 017 AA is still in preclinical trials for Alopecia areata (In adolescents, In children) in South Korea (HCell pipeline, September 2024)
28 Feb 2022 No recent reports of development identified for preclinical development in Alopecia areata(In adolescents, In children) in South Korea (Topical, Injection)
15 Jan 2018 Preclinical trials in Alopecia areata (In children, In adolescents) in South Korea (Topical)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com